The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

GSK GLAXOSMITHKLINE PLC ORD 25P




 Page 3 of 14

Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next |

Time/Date Code Headline Source Impact
18:08 16-Jan-2017 GSK Director/PDMR Shareholding RNS -1.65% Down
17:15 16-Jan-2017 GSK Director/PDMR Shareholding RNS -1.65% Down
17:04 16-Jan-2017 GSK Director/PDMR Shareholding RNS -1.65% Down
16:54 16-Jan-2017 GSK Director/PDMR Shareholding RNS -1.65% Down
16:01 16-Jan-2017 GSK Director/PDMR Shareholding RNS -1.65% Down
15:51 16-Jan-2017 GSK Director/PDMR Shareholding RNS -1.65% Down
16:40 13-Jan-2017 GSK Director/PDMR Shareholding RNS -1.14% Down
15:44 13-Jan-2017 GSK Director/PDMR Shareholding RNS -1.14% Down
14:29 13-Jan-2017 GSK Director/PDMR Shareholding RNS -1.14% Down
16:38 12-Jan-2017 GSK Director/PDMR Shareholding RNS -1.19% Down
16:51 10-Jan-2017 GSK Director/PDMR Shareholding RNS +0.14% Up
10:34 03-Jan-2017 GSK Total Voting Rights RNS +1.32% Up
14:03 20-Dec-2016 GSK ViiV starts HIV prevention study with cabotegravir RNS +1.76% Up
07:17 20-Dec-2016 GSK Blocklisting Application RNS +1.76% Up
07:00 20-Dec-2016 GSK ViiV announce phase III results for 2-drug regimen RNS +1.76% Up
15:19 19-Dec-2016 GSK Directorate Change RNS +2.51% Up
09:32 19-Dec-2016 GSK Phase III study start for closed triple in asthma RNS +2.51% Up
17:32 16-Dec-2016 GSK Treasury Stock RNS +2.86% Up
10:45 16-Dec-2016 GSK Director/PDMR Shareholding RNS +2.86% Up
09:11 13-Dec-2016 GSK Audit Tender Conclusion RNS +3.18% Up

 Page 3 of 14

Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next |



Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released
y = instrument's latest 7 closing prices before the news was released, including the day of the release of the news

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank “ - “ next to the line indicating the RNS issue.





Company Information
Updated Monthly
Company address C8 Gsk House, 980 Great West Road, Brentford, TW8 9GS, United Kingdom
Company website http://www.gsk.com
Market cap(in millions)* £ 82,028.13
Listing/Admission to trading 22 May 1972
Trading service SETS
Market Main Market
Listing category Premium Equity Commercial Companies
*The market capitalisation of companies reflects the London listed element only. These figures are approximate and are updated monthly.

Trading Information
23-Mar-17
FTSE index FTSE All-Share,FTSE Eurotop 300,FTSE 350 High Yield,FTSE 100,FTSE 350 (ex IT),FTSE techMARK All-Share,FTSE All-Share (ex IT),FTSE 350
FTSE sector Pharmaceuticals & Biotechnology
FTSE sub-sector Pharmaceuticals
Country of share register GB
Segment SET0
MiFID Status Regulated Market
Exchange market size 1,500
SEDOL 0925288
ISIN number GB0009252882



GLAXOSMITHKLINE share news analysis (GSK)